Search
VCA-894A
go.drugbank.com/drugs/DB18609InvestigationalVCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3'
PRG-A01
go.drugbank.com/drugs/DB18613InvestigationalPRG-A01 is a novel inhibitor of Cu, Zn-superoxide dismutase (SOD1) misfolding and aggregation.
Dipraglurant
go.drugbank.com/drugs/DB12733InvestigationalIt is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).
Butylphthalide
go.drugbank.com/drugs/DB12749InvestigationalButylphthalide has been used in trials studying the prevention of Restenosis.
Categories: Compounds used in a research, industrial, or household settingOpaganib
go.drugbank.com/drugs/DB12764InvestigationalOpaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered.
Higenamine
go.drugbank.com/drugs/DB12779InvestigationalHigenamine is under investigation in clinical trial NCT01451229 (Pharmacokinetics and Pharmacodynamics of Higenamine in Chinese Healthy Subjects).
Categories: Compounds used in a research, industrial, or household settingPegamotecan
go.drugbank.com/drugs/DB12842InvestigationalPegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue, and Gastroesophageal Cancer.
Categories: Compounds used in a research, industrial, or household settingApricitabine
go.drugbank.com/drugs/DB12855InvestigationalApricitabine has been used in trials studying the treatment of HIV Infections.
Indole-3-carbinol
go.drugbank.com/drugs/DB12881InvestigationalIndole 3 Carbinol is under investigation in clinical trial NCT00033345 (Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer).
Categories: Compounds used in a research, industrial, or household settingResmetirom
go.drugbank.com/drugs/DB12914ApprovedInvestigationalResmetirom is a thyroid hormone receptor-beta (THR-beta) agonist. … On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD